MENLO PARK, Calif., July 01, 2025 (GLOBE NEWSWIRE) -- Oruka Therapeutics, Inc. (“Oruka”) (Nasdaq: ORKA), a clinical-stage biotechnology company developing novel biologics designed to set a new standard for the treatment of chronic skin diseases including plaque psoriasis (PsO), today announced the promotion of Laura Sandler to Chief Operating Officer. Ms. Sandler, who joined Oruka in 2024 as SVP of Operations, brings over 20 years of biopharmaceutical leadership experience across clinical operations, develo ...

Core Viewpoint - Teva Pharmaceutical Industries Ltd. has released its Q2 2025 Aide Memoire to assist in financial modeling of its quarterly results, reflecting the company's ongoing commitment to delivering medicines globally [2][3]. Company Overview - Teva is a global biopharmaceutical leader with over 120 years of experience, focusing on innovation and the production of generics and biologics [3]. - The company operates in 57 markets with a workforce of 37,000 employees, dedicated to advancing health and addressing patient needs [3].

SAN DIEGO, June 25, 2025 (GLOBE NEWSWIRE) -- Maravai LifeSciences Holdings, Inc. (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, today announced that Rajesh “Raj” Asarpota has been appointed Executive Vice President (EVP) and Chief Financial Officer (CFO), effective June 30, 2025. He will succeed Kevin Herde, who is transitioning to an advisory role on the same date to support an effective transition. “We thank Kevin for his commitment to Marav ...

SAN DIEGO, June 09, 2025 (GLOBE NEWSWIRE) -- Maravai LifeSciences Holdings, Inc. (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, today announced the appointment of Bernd Brust as Chief Executive Officer (CEO) and a member of the Board of Directors, effective immediately. Mr. Brust succeeds William “Trey” Martin III in these roles. “This leadership transition reflects Maravai’s commitment to accelerating innovation, execution, and financial perfo ...

Core Viewpoint - Teva Pharmaceutical Industries Ltd. has announced the pricing and early acceptance results of its tender offers to purchase outstanding notes issued by its finance subsidiaries, with specific terms and conditions outlined in the Offer to Purchase dated May 19, 2025 [1][10]. Summary by Relevant Sections Tender Offer Details - The early acceptance results indicate the total consideration for each series of notes, with specific amounts tendered and accepted [2][8]. - The total maximum amount and pool tender caps for the offers are set at $1,550 million for Pool 1, $350 million for Pool 2, and $400 million for Pool 3 [2][3]. Acceptance Priority Levels - Notes tendered with Acceptance Priority Level 4 will be accepted in full without proration, while those with Levels 1, 2, and 5 will be accepted subject to proration factors of approximately 60.75%, 39.46%, and 36.66%, respectively [8][9]. Financial Conditions - The settlement of Teva's $2.3 billion senior notes offering on May 28, 2025, satisfied the financing condition for the tender offers [12]. - The purchase price for the Dollar Notes and Euro Notes will be paid in their respective currencies [12]. Timeline and Conditions - The initial settlement date is expected to occur on June 5, 2025, with the offers set to expire at 5:00 p.m. Eastern Time on June 17, 2025, unless extended or terminated earlier [11][9]. - Teva reserves the right to amend or waive conditions related to the offers [10]. Company Overview - Teva Pharmaceutical Industries Ltd. operates as a global biopharmaceutical leader, focusing on innovation and the production of generics and biologics, with a commitment to advancing health for over 120 years [16].

Core Viewpoint - Rosen Law Firm is reminding investors who purchased Actinium Pharmaceuticals, Inc. securities during the specified Class Period of the upcoming lead plaintiff deadline on May 27, 2025 [1]. Group 1: Class Action Details - Investors who purchased Actinium securities between October 31, 2022, and August 2, 2024, may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and interested parties can join by contacting Rosen Law Firm [3][6]. - The lawsuit alleges that during the Class Period, Actinium made false or misleading statements regarding its Iomab-B Biologics License Application, which may not meet FDA guidelines [5]. Group 2: Legal Representation - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a proven track record in securities class actions, highlighting its own success in this area [4]. - The firm has achieved significant settlements for investors, including over $438 million in 2019 alone, and has been recognized as a leader in securities class action settlements [4].

Core Insights - Oruka Therapeutics, Inc. is a clinical stage biotechnology company focused on developing novel biologics for chronic skin diseases, particularly plaque psoriasis [1][2] - The company aims to provide patients with significant freedom from chronic skin conditions by achieving high rates of complete disease clearance with infrequent dosing, potentially as little as once or twice a year [2] - Oruka is advancing a proprietary portfolio of antibodies engineered to target the core mechanisms of plaque psoriasis and other dermatologic and inflammatory diseases [2] Event Announcement - Oruka will present at the Jefferies Global Health Care Conference in New York on June 4, 2025, at 12:50 PM ET [1] - A webcast and replay of the presentation will be available on the Oruka investor events website [1] Company Information - Oruka Therapeutics is committed to setting a new standard in the treatment of chronic skin diseases through innovative biologics [2] - The company’s mission emphasizes achieving high rates of disease clearance for patients suffering from conditions like plaque psoriasis [2]

Core Viewpoint - Teva Pharmaceutical Industries Ltd. has published its 2024 Healthy Future Report, highlighting its achievements in sustainability and access to medicines, which are integral to its long-term growth strategy [1][5]. Healthy People - Teva launched two new access to medicines programs, bringing the total to nine, exceeding its target of eight by 2025. The company donated approximately 18 million doses of medicine valued at $23 million and provided 2.2 million doses at low cost, benefiting 187,000 patients. Additionally, five programs focused on strengthening health systems and capacity building, aiding around 56,000 individuals [2]. Healthy Planet - Teva achieved a 29% reduction in absolute scope 1 and 2 greenhouse gas emissions from 2019 levels, surpassing its 25% target by 2025 ahead of schedule. Furthermore, 73% of applicable Teva sites met safe discharge levels for antibiotics, reducing environmental pollution. A pilot program in Germany educated over 65,000 healthcare professionals, resulting in approximately 389,000 patient interactions regarding appropriate antibiotic use [3][8]. Healthy Business - Teva emphasized integrity in operations, with over 99% of employees retrained on compliance and ethics, meeting its annual target. Additionally, 41% of significant suppliers were evaluated for sustainability performance, and all high-risk third-party partners underwent evaluation through Teva's Third-Party Due Diligence tool, promoting responsible sourcing practices [4][8]. Recognition and Impact - Teva received improved sustainability scores from organizations such as Sustainalytics, MSCI, and EcoVadis, along with awards for its programs and progress. The company's generic medicines contributed to $39.7 billion in savings for healthcare systems across 22 countries [5][8].

Charles River Laboratories International (CRL) Q1 2025 Earnings Call May 07, 2025 09:00 AM ET Company Participants Todd Spencer - Vice President, Investor RelationsJames Foster - Chairman, President and CEOFlavia Pease - Corporate Executive VP & CFOElizabeth Anderson - Senior Managing DirectorDave Windley - Managing DirectorMichael Ryskin - Managing DirectorKyle Crews - Equity Research AssociatePatrick Donnelly - Managing DirectorCasey Woodring - Vice President - Equity ResearchCharles Rhyee - Managing Dire ...

Core Viewpoint - Despite major market indexes like the S&P 500 struggling in 2025, certain mid-cap stocks in the medical and biotechnology sectors are showing strong performance and growth potential, presenting investment opportunities for those looking beyond large-cap stocks [1]. Group 1: Penumbra - Penumbra, Inc. is a high-growth medical devices company with a market capitalization of $11.3 billion, focusing on neuro and vascular interventions [2][3]. - The stock has increased by 23% year-to-date and 43% over the past 12 months, demonstrating resilience amid broader market volatility [2][3]. - The company reported Q1 earnings of $0.83 per share, exceeding estimates by $0.17, with revenue rising 16.3% year-over-year to $324.1 million [3]. - Analysts maintain a Moderate Buy consensus rating, with a price target of $302.40, indicating further upside potential [4]. Group 2: TransMedics Group - TransMedics Group is a commercial-stage medical technology company focused on organ transplant procedures, with a market cap of $92.18 million [6]. - The stock has surged nearly 48% year-to-date, following a breakout above key resistance levels [7]. - Analysts have a Moderate Buy consensus rating, with a price target of $124.20, suggesting up to 35% upside from current levels [8]. Group 3: ADMA Biologics - ADMA Biologics is a biopharmaceutical company specializing in plasma-derived biologics, with a market capitalization of $5.6 billion [10]. - The stock has risen 38% year-to-date and is trading just 7% below its all-time high [10][11]. - The company has a P/E ratio of 29 and a forward P/E of 23, with projected EPS growth of 45% in 2025, supported by a Buy rating from all four analysts covering the stock [11].